Semax and selank blends: what the science says vs. TikTok

What did @cinda5585 actually say?

The creator says she has been taking a semax/selank blend from a company called Enzymic for a few weeks and has experienced no side effects. Her headline claim is striking: "my stuttering is not there," which she attributes directly to the blend reducing her anxiety. She connects years of stuttering to anxiety, says the peptides got that anxiety "in need control," and encourages viewers to click her bio link to buy the product. She also mentions taking it "every other day" or "as needed" going forward.

Worth noting: she only has experience with the pre-mixed blend, not the individual compounds separately, and she's transparent about that limitation. She also includes the standard caveat that individual results will differ. The affiliate link in the bio is relevant context, since this is a promotional update, not a neutral personal diary entry.

Does the science back this up?

There is real, peer-reviewed research on both semax and selank, mostly from Russian institutions, and the signal on anxiety reduction is genuinely interesting. But the evidence base is nowhere near strong enough to make confident claims about stuttering reduction in humans.

Selank is a synthetic analogue of the endogenous peptide tuftsin. A 2012 study by Semenova et al. published in CNS Drug Reviews found anxiolytic effects in animal models, with a proposed mechanism involving GABA-A receptor modulation and serotonin stabilization. A 2014 open-label Russian trial (Zozulya et al., Zhurnal Nevrologii i Psikhiatrii) reported reduced anxiety in generalized anxiety disorder patients. These are not randomized controlled trials with large Western samples, and open-label designs carry significant placebo risk.

Semax has slightly stronger nootropic data, with some evidence of BDNF upregulation (Dolotov et al., 2006, Journal of Molecular Neuroscience). The theory that improved cognitive-emotional regulation could reduce anxiety-linked speech disruptions is plausible but entirely speculative at this point. No published study has examined semax or selank specifically for stuttering.

What did they get wrong (or right)?

She got the anxiety-stuttering connection right. Developmental stuttering has a well-documented relationship with anxiety, though researchers debate whether anxiety is a cause, consequence, or amplifier. A 2018 review by Iverach and Rapee in Journal of Fluency Disorders found that people who stutter have significantly elevated rates of social anxiety disorder. If selank reduced her anxiety meaningfully, improved fluency is a biologically coherent outcome, even if unproven.

What she got wrong, or at least oversimplified, is the certainty. Saying "that's how I know for a fact those work" after a few weeks with no control condition is not how you know for a fact anything. Weeks-long self-reports are also notoriously susceptible to placebo response, expectation bias, and natural fluctuation in anxiety symptoms. She also does not disclose her affiliate relationship clearly, which matters when she's directing 13,000 viewers to a purchase link.

What should you actually know?

Semax and selank are not FDA-approved drugs for any indication. They exist in a regulatory gray zone where some compounding pharmacies and supplement vendors sell them, but quality control varies enormously between suppliers. Neither compound has completed Phase III clinical trials in the United States.

If you're dealing with anxiety-related stuttering, there are evidence-based options. Cognitive behavioral therapy combined with speech therapy has solid trial data behind it. SSRIs and SNRIs have been studied for social anxiety with established safety profiles. These are not sexy TikTok content, but they have replicated results across large populations.

The semax/selank combination as a blend also has zero published pharmacokinetic or safety data. You are essentially trusting a manufacturer's internal testing, if any exists. The creator says she has no side effects, which is genuinely good to hear, but absence of short-term side effects in one person is not a safety profile. Nasal peptide delivery also raises bioavailability questions that the creator does not address because she probably does not know and cannot be expected to know.

Anyone seriously considering these compounds should have that conversation with a licensed clinician who understands peptide pharmacology, not an affiliate video.